Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Part of paid clinical trials in St. Petersburg, Florida.
- Sponsor
- Skyline Therapeutics (US) Inc.
- Study ID
- NCT05986864
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Neovascular Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SKG0106 — GENETICSKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
Study Details
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Key Dates
- Start date
- Feb 23, 2024
- Status verified
- Jan 2025
- Primary completion
- Jan 31, 2026
- Completion
- Jan 30, 2026
Study Design
- Enrollment
- 68 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase I: Low doseSKG0106 One-Time Intraocular Injection Dose Level 1
- Experimental: Phase I: Medium doseSKG0106 One-Time Intraocular Injection Dose Level 2
- Experimental: Phase I: High doseSKG0106 One-Time Intraocular Injection Dose Level 3
Primary Outcome Measure
Characteristics of dose limiting toxicities (DLTs) [ Time Frame: 4 Weeks ]
Central Contacts
- Yongqin Wang+86 18616737445
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Retina Vitreous Associates of Florida - Saint Petersburg | St. Petersburg | Florida | 33711 | - |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | - |
| Retina Consultants of Texas | Katy | Texas | 77494 | Marie Chin Charles C Wykoff, MD (PRINCIPAL_INVESTIGATOR) |
| Wagner Kapoor Research Institute | Norfolk | Virginia | 23502 | Chris Riebling Alan Wagner, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in St. Petersburg, FL
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMDPHASE3 · Recruiting · Jaeb Center for Health Research · Glendale, California